
MARIMED INC.
93
Recent news includes MariMed’s launch of hemp-derived THC products under its Vibations™ brand in Rhode Island and public reporting of quarterly earnings.
- MariMed launched hemp-derived THC products under its Vibations™ brand in Rhode Island in January 2026 [N1].
- MariMed reported third quarter 2024 earnings publicly [N1].
MariMed Inc. operates as a multi-state cannabis operator (MSO) in the United States, headquartered in Norwood, Massachusetts. The company develops, owns, and manages state-licensed, regulatory-compliant facilities for cultivation, production, and dispensing of medicinal and adult-use cannabis products. MariMed has developed proprietary brands such as Nature’s Heritage™, Betty’s Eddies™, Bubby’s Baked™, Vibations™, and InHouse™, which are distributed in cannabis-legal states. The company operates both wholesale distribution to other dispensaries and retail operations under the Thrive™ brand. MariMed holds 33 cannabis licenses across six states and is vertically integrated in Illinois, Maryland, Massachusetts, and Delaware. The company also manages cultivation and manufacturing operations in Pennsylvania and has licensing agreements for product distribution in New York and Pennsylvania. MariMed’s strategic growth plan emphasizes expanding brand revenue, enhancing cultivation and processing capabilities, launching innovative products, broadening distribution, and growing its retail footprint. The company invests in customer experience, staff training, and loyalty programs to drive sales. MariMed monitors regulatory developments closely, especially regarding hemp-derived cannabinoid products. As of September 30, 2026, the company reported a net loss of $3.5 million and maintains liquidity with a current ratio of 0.9. The management team has extensive industry experience, and proprietary processing techniques are protected by confidentiality agreements.
MariMed Inc. is a vertically integrated multi-state cannabis operator in the U.S., developing and managing cultivation, production, and retail facilities. The company owns proprietary cannabis brands distributed through wholesale and retail channels across multiple states. MariMed reported a net loss of $3.5 million for Q3 2026 with a current ratio of 0.9 as of September 30, 2026. The company continues to execute its strategic growth plan focused on brand expansion, product innovation, and retail footprint growth while monitoring evolving regulatory environments. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
MariMed’s established presence as a multi-state operator with vertically integrated operations and a portfolio of recognized proprietary brands positions it to capitalize on expanding cannabis markets. The company’s strategic focus on product innovation, brand expansion, and retail growth aligns with evolving consumer preferences. Investments in cultivation and processing capabilities aim to enhance product quality and consistency. MariMed’s retail operations provide valuable customer insights that inform product development and distribution strategies. The company’s experienced management team and disciplined capital allocation support execution of growth initiatives. Expansion into hemp-derived cannabinoid products offers additional market opportunities, albeit currently limited in scale.
MariMed operates in a highly regulated and evolving industry where cannabis remains illegal under federal law, creating legal and operational risks. Regulatory changes, especially concerning hemp-derived cannabinoid products, could restrict product offerings or impose additional compliance costs. The company reported a net loss in the latest quarter and maintains a current ratio below 1, indicating liquidity constraints. Competition from other multi-state and single-state operators with comparable or superior products could impact market share and sales. Execution of growth strategies depends on regulatory approvals, capital availability, and market conditions. Changes in consumer preferences or adverse regulatory developments could negatively affect MariMed’s business and financial performance.
MariMed’s competitive advantages include its portfolio of proprietary and award-winning cannabis brands, vertically integrated operations across multiple states, and a well-established retail footprint under the Thrive™ brand. The company’s experienced management team with deep industry knowledge supports operational execution and regulatory compliance. MariMed’s ability to produce premium cannabis products at a low cost structure and its investments in customer experience and loyalty programs contribute to brand strength and market penetration. Barriers to entry in the cannabis industry, such as licensing requirements, capital investment, and regulatory compliance, further support MariMed’s competitive position. Confidential proprietary processing techniques and trademarks provide additional protection for its intellectual property.
• Regulatory Risk: Cannabis remains illegal under U.S. federal law, and evolving federal and state regulations, including potential restrictions on hemp-derived products, pose compliance and operational risks [S1].
• Liquidity and Financial Performance Risk: MariMed reported a net loss of $3.5 million for Q3 2026 and had a current ratio of 0.9 as of September 30, 2026, indicating potential liquidity constraints [S2].
• Competitive Risk: The company faces competition from other multi-state and single-state cannabis operators with comparable products, which could impact sales and market share [S1].
• Execution Risk: Growth initiatives depend on regulatory approvals, capital availability, and market conditions, which may affect the company’s ability to expand its brand portfolio and retail footprint [S1].
• Product and Market Risk: Changes in consumer preferences or adverse regulatory developments could limit product offerings or reduce demand for MariMed’s cannabis and hemp-derived products [S1].
Business trends: Expansion of proprietary cannabis brands, retail footprint growth, and entry into hemp-derived cannabinoid products amid evolving regulatory landscape.
Execution milestones: Continued integration of acquisitions, enhancement of cultivation and processing capabilities, and expansion of retail and wholesale distribution.
Key risks: Regulatory uncertainty due to federal cannabis illegality, liquidity constraints, competitive pressures, and execution risks related to market expansion and product offerings.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- MariMed Inc. is a multi-state cannabis operator headquartered in Norwood, Massachusetts, focused on medicinal and adult-use cannabis products in the United States [S1].
- The company develops, owns, and manages seed-to-sale state-licensed, regulatory-compliant facilities for cultivation, production, and dispensing of cannabis [S1].
- MariMed has proprietary brands including Nature’s Heritage™, Betty’s Eddies™, Bubby’s Baked™, Vibations™, and InHouse™, which are recognized and award-winning in multiple states [S1].
- The company operates both wholesale and retail cannabis businesses, distributing products to hundreds of dispensaries and operating its own branded dispensaries under the Thrive™ brand [S1].
- MariMed’s retail stores are located in Massachusetts, Delaware, Illinois, Maryland, and Ohio, with vertical integration (cultivation, manufacturing, retail) in Illinois, Maryland, Massachusetts, and Delaware [S1].
- The company has 33 cannabis licenses across six states and manages additional operations in Pennsylvania and New York through partnerships and licensing agreements [S1].
- MariMed expanded into hemp-derived cannabinoid products in 2025, leveraging existing brand and distribution capabilities, though this remains a limited part of the business [S1].
- The company’s strategic growth plan focuses on expanding brand revenue through cultivation and processing enhancements, new product development, distribution expansion, and retail footprint growth [S1].
- MariMed invests in customer experience, retail staff training, and loyalty programs to drive retail and wholesale sales [S1].
- The company had 923 employees as of December 31, 2025, with 808 full-time [S1].
- MariMed reported a net loss of $3.5 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.01 [S2].
- As of September 30, 2026, MariMed had cash and equivalents of $6.6 million, current assets of $61.4 million, current liabilities of $67.9 million, a current ratio of 0.9, and a cash ratio of 0.1 [S2].
- The company’s operations comply with applicable state and local laws, though cannabis remains illegal under U.S. federal law [S1].
- MariMed monitors evolving federal and state regulatory developments, including potential restrictions on hemp-derived cannabinoid products [S1].
- The company’s management team has extensive cannabis industry experience, with key executives having over a decade in the sector [S1].
- MariMed’s proprietary processing and manufacturing techniques are confidential and protected by confidentiality agreements [S1].
- Recent news includes MariMed launching hemp-derived THC products under its Vibations™ brand in Rhode Island in January 2026 [N1].
- MariMed reported third quarter 2024 earnings and other quarterly results publicly [N1].
Generated 2026-11-13
- S1 | 2026-03-12 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-13 | www.nasdaq.com | EuroDry Ltd. Reports Third Quarter 2026 Results and Newbuilding Contract | https://www.nasdaq.com/articles/eurodry-ltd-reports-third-quarter-2026-results-and-newbuilding-contract
- N2 | 2026-11-13 | www.nasdaq.com | Neonode Inc. Reports Quarter Ended September 30, 2026 Financial Results | https://www.nasdaq.com/articles/neonode-inc-reports-quarter-ended-september-30-2026-financial-results
- N3 | 2026-11-13 | www.nasdaq.com | Upwork Inc. Expands Restructuring Plan to Reduce Workforce by Approximately 37% | https://www.nasdaq.com/articles/upwork-inc-expands-restructuring-plan-reduce-workforce-approximately-37
- N4 | 2026-11-13 | www.nasdaq.com | The AI Trade Just Cracked. Here’s the Price at Which I’d Start Buying Nvidia. | https://www.nasdaq.com/articles/ai-trade-just-cracked-heres-price-which-id-start-buying-nvidia
- N5 | 2026-11-13 | www.nasdaq.com | Vishay Intertechnology, Inc. to Invest $56.4 million in India Semiconductor Joint Venture | https://www.nasdaq.com/articles/vishay-intertechnology-inc-invest-564-million-india-semiconductor-joint-venture
- N6 | 2026-11-13 | www.nasdaq.com | Centrus Energy Corp. Signs Definitive Contracts with Oklo to Supply HALEU with Deliveries Beginning in 2029 | https://www.nasdaq.com/articles/centrus-energy-corp-signs-definitive-contracts-oklo-supply-haleu-deliveries-beginning-2029
- N7 | 2026-11-13 | www.nasdaq.com | Warren Buffett's Successor, Greg Abel, Has Over 35% of Berkshire Hathaway's $359 Billion Portfolio Invested in Just 2 Undeniable Winners | https://www.nasdaq.com/articles/warren-buffetts-successor-greg-abel-has-over-35-berkshire-hathaways-359-billion-portfolio
- N8 | 2026-11-13 | www.nasdaq.com | Carter Bankshares, Inc. Announces $10,000,000 Common Share Repurchase Program | https://www.nasdaq.com/articles/carter-bankshares-inc-announces-10000000-common-share-repurchase-program
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


